Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, announced that CEO Michael A. Metzger will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 10:30 a.m. PT/ 1:30 p.m. ET. Interested parties can access a live webcast of the fireside chat through the Investor section of Syndax's website, where a replay will also be available temporarily.
Syndax Pharmaceuticals (NASDAQ: SNDX), un'azienda biofarmaceutica in fase commerciale focalizzata sulle terapie per il cancro, ha annunciato che il CEO Michael A. Metzger presenterà al 43° Annual J.P. Morgan Healthcare Conference. La presentazione è programmata per martedì 14 gennaio 2025, alle 10:30 ora del Pacifico / 13:30 ora dell'Est. Le parti interessate possono accedere a una diretta web della chiacchierata informale attraverso la sezione per gli investitori del sito web di Syndax, dove sarà disponibile anche una registrazione temporanea.
Syndax Pharmaceuticals (NASDAQ: SNDX), una compañía biofarmacéutica en etapa comercial centrada en terapias para el cáncer, anunció que el CEO Michael A. Metzger presentará en la 43ª Conferencia Anual de Salud de J.P. Morgan. La presentación está programada para el martes 14 de enero de 2025, a las 10:30 a.m. PT / 1:30 p.m. ET. Las partes interesadas pueden acceder a una transmisión en vivo de la charla a través de la sección de inversores en el sitio web de Syndax, donde también estará disponible una repetición temporalmente.
Syndax Pharmaceuticals (NASDAQ: SNDX)는 암 치료에 중점을 둔 상업 단계의 생명공학 회사로, CEO Michael A. Metzger가 제43회 J.P. Morgan Healthcare Conference에서 발표할 것이라고 발표했습니다. 발표는 2025년 1월 14일 화요일 오전 10:30 PT/오후 1:30 ET에 예정되어 있습니다. 관심 있는 당사자는 Syndax 웹사이트의 투자자 섹션을 통해 대화의 생중계를 시청할 수 있으며, 녹화본도 일정 기간 제공될 예정입니다.
Syndax Pharmaceuticals (NASDAQ: SNDX), une entreprise biopharmaceutique en phase commerciale axée sur les thérapies contre le cancer, a annoncé que le PDG Michael A. Metzger présentera à la 43e Conférence Annuelle J.P. Morgan Healthcare. La présentation est prévue pour le mardi 14 janvier 2025, à 10h30 PT / 13h30 ET. Les parties intéressées peuvent accéder à un streaming en direct de la conversation sur la section Investisseurs du site Web de Syndax, où un rediffusion sera également disponible temporairement.
Syndax Pharmaceuticals (NASDAQ: SNDX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Krebstherapien konzentriert, gab bekannt, dass CEO Michael A. Metzger auf der 43. jährlichen J.P. Morgan Healthcare Conference präsentieren wird. Die Präsentation ist für Dienstag, den 14. Januar 2025, um 10:30 Uhr PT / 13:30 Uhr ET geplant. Interessierte Parteien können über den Investorenbereich der Syndax-Website auf einen Live-Stream des Gesprächs zugreifen, wo auch eine vorübergehende Aufzeichnung verfügbar sein wird.
- None.
- None.
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original content:https://www.prnewswire.com/news-releases/syndax-announces-presentation-at-43rd-annual-jp-morgan-healthcare-conference-302343500.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
When is Syndax (SNDX) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Syndax's (SNDX) J.P. Morgan Healthcare Conference presentation?
Who will represent Syndax (SNDX) at the 2025 J.P. Morgan Healthcare Conference?
What type of presentation will Syndax (SNDX) give at the J.P. Morgan Healthcare Conference?
